Viking Therapeutics faces investor scrutiny after reporting a Q1 net loss of $1.37 per share, resulting in a 1% decline in stock value while analysts reveal mixed sentiments on the company's outlook. Despite the disappointing earnings, 62% of analysts view the stock as undervalued due to its promising lead drug candidate VK2735 and a substantial price target increase to $102.0. Furthermore, higher-than-expected R&D expenses may raise cash flow concerns, although the company maintains a runway until 2028 as it approaches critical Phase 3 trial completions.
“Viking Therapeutics · is headquartered in · San Diego, United States · true”
“Viking Therapeutics · current stock price · VKTX · $28.47”
“Viking Therapeutics · price target · Wall Street analysts · $96.38”
“Viking Therapeutics · percentage increase · price target · 238.53%”
“Viking Therapeutics · analyst rating · VKTX · Buy”
“Viking Therapeutics · analyst ratings breakdown · Strong Buy · 50%”
“Viking Therapeutics · analyst ratings breakdown · Buy · 38%”
“Viking Therapeutics · analyst ratings breakdown · Hold · 13%”
“Viking Therapeutics · analyst ratings breakdown · Sell · 0%”
“Viking Therapeutics · analyst ratings breakdown · Strong Sell · 0%”
“Viking Therapeutics · lead drug candidate · VK2735 · GLP-1/GIP dual agonist”
“Viking Therapeutics · pipeline products · VK2809 and VK0214 · favorable results in clinical trials”